Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer

Oncologist

Volumn 18, Issue 4, 2013, Pages 377-378

  Wolpin, Brian M ^a   Ng, Kimmie ^a   Zhu, Andrew X ^b   Abrams, Thomas ^a   Enzinger, Peter C ^a   McCleary, Nadine J ^a   Schrag, Deborah ^a   Kwak, Eunice L ^b   Allen, Jill N ^b   Bhargava, Pankaj ^a,c   Chan, Jennifer A ^a   Goessling, Wolfram ^a   Blaszkowsky, Lawrence S ^b   Supko, Jeffrey G ^b   Elliot, Meaghan ^a   Sato, Kaori ^a   Regan, Eileen ^a   Meyerhardt, Jeffrey A ^a   Fuchs, Charles S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c AVEO ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; TIVOZANIB;

ARTICLE; CANCER CONTROL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NEOPLASM STAGING; PHENYLUREA COMPOUNDS; QUINOLINES; SIROLIMUS; TREATMENT OUTCOME;

EID: 84877064638     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0378     Document Type: Article

References (0)